AMLX:NSD-Amylyx Pharmaceuticals Inc. Common Stock (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 8.57

Change

+0.12 (+1.42)%

Market Cap

USD 0.49B

Volume

0.30M

Avg Analyst Target

USD 30.67 (+257.84%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Amylyx Pharmaceuticals Inc. Common Stock (AMLX) Stock Analysis:
Based on the Amylyx Pharmaceuticals Inc. Common Stock stock forecasts from 5 analysts, the average analyst target price for Amylyx Pharmaceuticals Inc. Common Stock is USD 30.67 over the next 12 months. Amylyx Pharmaceuticals Inc. Common Stock’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Amylyx Pharmaceuticals Inc. Common Stock is Very Bearish, which is based on 0 positive signals and 2 negative signals. At the last closing, Amylyx Pharmaceuticals Inc. Common Stock’s stock price was USD 8.57. Amylyx Pharmaceuticals Inc. Common Stock’s stock price has changed by -1.95% over the past week, -18.46% over the past month and 0% over the last year.

About

Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor co ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+4.86 (+0.71%)

USD74.91B 9.70 7.18
VRTX Vertex Pharmaceuticals Incorpo..

+2.36 (+0.88%)

USD68.63B 28.32 19.22
MRNA Moderna Inc

-1.21 (-0.92%)

USD54.74B 4.05 2.75
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+0.17 (+0.11%)

USD39.61B 3.12 1.86
RPRX Royalty Pharma plc

+0.47 (+1.18%)

USD27.00B 29.25 15.23
SGEN Seagen Inc

+3.00 (+2.25%)

USD25.65B 55.02 44.86
GMAB Genmab A/S

-0.53 (-1.74%)

USD20.43B 60.76 5.35
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
ARGX argenx SE

+3.30 (+1.05%)

USD17.25B N/A N/A

ETFs Containing AMLX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.49B 75% C 59% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.19 43% F 39% F
Price / Cash Flow Ratio -6.59 74% C 74% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -188.05% 15% F 7% F
Return on Invested Capital 76.40% 96% A 97% A+
Return on Assets -86.34% 5% F 2% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 3.94 59% F 41% F
Short Percent 8.86% 27% F 20% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.